Ted Shih

724 total citations
9 papers, 524 citations indexed

About

Ted Shih is a scholar working on Oncology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ted Shih has authored 9 papers receiving a total of 524 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Genetics and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ted Shih's work include Chronic Lymphocytic Leukemia Research (4 papers), HER2/EGFR in Cancer Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Ted Shih is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), HER2/EGFR in Cancer Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Ted Shih collaborates with scholars based in United States, United Kingdom and Spain. Ted Shih's co-authors include Celeste Lindley, Sandhya Girish, Yu‐Waye Chu, Amita Joshi, Manish Gupta, Joo‐Hee Yi, Timothy J. Carrothers, E. Claire Dees, Howard A. Burris and Dan Lu and has published in prestigious journals such as Blood, Cancer Research and Clinical Therapeutics.

In The Last Decade

Ted Shih

9 papers receiving 513 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ted Shih United States	6	222	201	107	92	86	9	524
Julie Madden United Kingdom	9	212 1.0×	214 1.1×	38 0.4×	82 0.9×	49 0.6×	14	502
Mélanie Briand France	16	139 0.6×	274 1.4×	83 0.8×	194 2.1×	87 1.0×	35	648
Giuseppe Gullo Ireland	13	368 1.7×	271 1.3×	88 0.8×	154 1.7×	151 1.8×	42	692
Thuy Trinh Germany	11	147 0.7×	194 1.0×	97 0.9×	92 1.0×	129 1.5×	20	501
A Harłozińska Poland	14	219 1.0×	234 1.2×	103 1.0×	76 0.8×	67 0.8×	55	587
Tamahiro Nishihara Japan	11	266 1.2×	138 0.7×	73 0.7×	98 1.1×	52 0.6×	27	442
Stephen Castaneda United States	10	356 1.6×	217 1.1×	76 0.7×	83 0.9×	143 1.7×	14	685
Karel Cwiertka Czechia	10	247 1.1×	115 0.6×	40 0.4×	108 1.2×	123 1.4×	45	436
Xiaohong Yan United States	13	364 1.6×	233 1.2×	57 0.5×	109 1.2×	157 1.8×	50	610
Sherry Yang United States	10	305 1.4×	210 1.0×	65 0.6×	115 1.3×	60 0.7×	32	645

Countries citing papers authored by Ted Shih

Since Specialization

Citations

This map shows the geographic impact of Ted Shih's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ted Shih with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ted Shih more than expected).

Fields of papers citing papers by Ted Shih

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ted Shih. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ted Shih. The network helps show where Ted Shih may publish in the future.

Co-authorship network of co-authors of Ted Shih

This figure shows the co-authorship network connecting the top 25 collaborators of Ted Shih. A scholar is included among the top collaborators of Ted Shih based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ted Shih. Ted Shih is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Searle, Emma, Francesco Forconi, Kim Linton, et al.. (2023). Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies. Blood. 142(Supplement 1). 4473–4473. 23 indexed citations

Patnaik, Mrinal M., David A. Sallman, Abhishek A. Mangaonkar, et al.. (2020). Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 136(7). 909–913. 31 indexed citations

Janakiram, Murali, Ravi Vij, David S. Siegel, et al.. (2020). A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma. Blood. 136(Supplement 1). 3–3. 4 indexed citations

Tam, Constantine S., Gavin Cull, Stephen Opat, et al.. (2019). An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies. Blood. 134(Supplement_1). 1594–1594. 7 indexed citations

Gupta, Manish, Bei Wang, Timothy J. Carrothers, et al.. (2013). Effects of Trastuzumab Emtansine (T‐DM1) on QT Interval and Safety of Pertuzumab Plus T‐DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Clinical Pharmacology in Drug Development. 2(1). 11–24. 32 indexed citations

Lu, Dan, Howard A. Burris, Bei Wang, et al.. (2012). Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Current Drug Metabolism. 13(7). 911–922. 30 indexed citations

Lu, Dan, et al.. (2010). Abstract P3-14-06: Pharmacokinetic (PK) Interaction Potential of Trastuzumab-DM1 (T-DM1) and Pertuzumab (P) in Pts with HER2-Positive, Locally Advanced or MBC: Results from a Phase 1b/2 Study. Cancer Research. 70(24_Supplement). P3–14. 2 indexed citations

Shih, Ted, et al.. (2008). Pharmacogenetics: From Bench Science to the Bedside. Drug Information Journal. 42(5). 503–513. 1 indexed citations

Shih, Ted & Celeste Lindley. (2006). Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clinical Therapeutics. 28(11). 1779–1802. 394 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact